Redeye updates its estimates and fair value range after Physitrack’s stable Q2 2023 report, which came in close to our forecasts. We find the c25% organic growth, combined with effective cost management in the face of ongoing challenging market conditions, to be encouraging. We raise our base case to SEK41(SEK38) per share.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Physitrack - Steady state

© Modular Finance, source Nordic Press Releases